Introduction
Alzheimer's disease (AD) is the most common dementia subtype accounting for nearly 80% of all cases with the number of those affected likely to rise considerably with increasing life expectancy [1] . There are currently more than 815,000 people with dementia in the UK (about 1.3% of the population) and 1 in 14 persons > 65 years have AD [2] . High prevalence rates have also been reported in the United States of America, with 1 in 9 individuals aged 65 years or more diagnosed with AD, increasing to 1 in 3 persons over the age of 85 years [3] .
Chronic kidney disease (CKD) is characterised by a gradual loss of kidney function over months or years and identified by serial measurements of serum creatinine and estimated glomerular filtration rate (eGFR). An eGFR < 60 ml/min/1.73m 2 has been recognised as a potential risk factor for dementia [4] [5] [6] [7] . The global prevalence of CKD is estimated at 11-13%, increasing with age to almost 28% in those 70 years or older [8] . Both the kidneys and brain are susceptible to vascular damage with similar haemodynamic and physiological characteristics and risk factors that include diabetes mellitus, hypertension and hyperlipidemia [9, 10] . Renal dysfunction also accelerates vascular ageing and calcification, including the vasculature proximal to the brain, such as the circle of Willis [11] , manifesting in structural alterations and increased risk of cerebrovascular disease [12] .
In preclinical dementia, symptomless but pathogenic changes within the brain include abnormal protein deposition culminating in neuronal death. Amyloid-β (Aβ) is the hallmark constituent of AD plaques and renal clearance has been proposed as a mechanism that aids the removal of cerebral Aβ [13] . An imbalance between the processes of production and clearance leads to Aβ accumulation and AD development and has become a therapeutic target of diseasemodifying agents [14] . CKD patients undergoing dialysis have been reported to have serum Aβ levels similar to cognitively intact controls, while those with CKD not receiving dialysis had relatively higher serum Aβ levels that were negatively correlated with eGFR [15] . Systemic reduction in serum Aβ following haemodialysis has also been demonstrated [16] with associated improvement in cognitive function [17] . Furthermore, animal studies have shown renal clearance of peripheral Aβ has led to reduced cerebral levels in mice [18] . As such, the objective of this study was to compare renal function determined by eGFR, between individuals with AD and cognitively intact controls, controlling for potential confounding factors.
Materials and Methods

Study design and recruitment
A cross-sectional, case-control study design was used to compare prevalent AD cases to cognitively intact controls. All recruitment and testing was undertaken between August 2006
and 2008 by one investigator (MW) and has been described elsewhere [19] . An opportunistic recruitment strategy was used with probable AD cases identified in a non-systematic fashion A variety of recruitment strategies were employed in the enrolment of controls from several sources. Firstly, carers of patients attending any outpatient clinic in the study hospital were approached. Secondly, a university press release invited participation in the study. Thirdly, a series of talks given to AD patient-support groups in the region led to further volunteers coming forward. All participants provided informed consent prior to their entry into the study.
Exclusion criteria for controls included age under 65 years or a Mini-Mental State Examination (MMSE) score below 26 out of 30. Ethics and governance approval was obtained prior to commencement of the study, which adhered to the tenets of the Declaration of Helsinki.
Data collection
Upon enrolment, all study participants underwent an assessment that involved measuring blood pressure, drawing a blood sample and performing a MMSE. The final component of the assessment involved the completion of questionnaires via interviews with the subject, as well as their carer when appropriate.
Blood taken from participants using standard venepuncture was used to measure serum creatinine for eGFR using the CKD-EPI equation and for DNA extraction to determine APOE e4 genotype using a 'Sequenom IPlex assay' as well as other blood measures. A family history of AD, medication use and all co-morbid health conditions were documented as present or absent as determined by self-report or consultation of medical notes. Smoking history was measured as a cumulative dose in pack-years.
Statistical Analysis
Summary statistics for continuous variables and relative frequencies by group were calculated. 14) , and use of beta blockers. To examine the association between AD severity and eGFR, a sensitivity analysis was undertaken using multinomial logistic regression. AD severity was categorised by MMSE score: Severe: 0-9;
Moderate: 10-20; Mild: 21-26; and pre-mild ≥ 27. Pre-mild AD was used as the reference category. The sensitivity analysis was adjusted for age, number of APOE e4 alleles, SBP, smoking pack-years, educational attainment and use of beta blockers. All statistical analyses were performed using SPSS statistics version 23 (IBM Corp., Armonk, NY).
Results
Demographic and clinical characteristics of the study population (n=570) are presented in 
Discussion
We found no significant association between eGFR and AD in this case-control study of 570 participants in an analysis adjusted for established AD risk factors. Additionally, we found no association between eGFR and disease severity as defined by MMSE score in AD cases only.
Our findings support previous reports that showed no association between eGFR and cognitive impairment [6, [20] [21] [22] , but contrast to those that did report a significant association [5, 9, [23] [24] [25] [26] [27] [28] [29] [30] . In addition, other studies also reported significant associations between renal impairment characterised by the presence of microalbuminuria and cognitive impairment [10, 20, 21, 31] . A recent meta-analysis of five population based prospective studies included 27,805 participants, demonstrated a non-significant increased risk of cognitive impairment or dementia in those with an eGFR < 60 ml/min/1.73m 2 , with a significant association found only in those with albuminuria [7] .
Unlike previous studies that examined cognitive impairment or dementia, we focused specifically on eGFR in AD. In an earlier study by this group with a smaller sample size and better renal function (eGFR > 60 ml/min/1.73m 2 ), an association between lower eGFR in 83
AD cases was identified compared to cognitively intact controls which remained significant following adjustment for known risk factors [4] . Other case-control studies of similar size have also reported lower eGFR in AD cases compared to controls [32, 33] providing some support for the hypothesis that reduced renal function contributes to impaired Aβ clearance and increased cerebral deposition [13] [14] [15] [16] [17] [18] 34] . Our current findings support data from the Cardiovascular Health Cognition Study in 3,349 individuals, where an association with serum creatinine and vascular dementia was identified but not in those with AD [35] . Our findings were based on a largely clinically derived sample of older participants (mean age 78) with unexpectedly poor renal function compared to the same age group in other cohorts [36] for both cases and controls (eGFR = 37 ml/min/1.73m 2 ). Rates of hypertension and diabetes were not higher than expected in cases or controls. The low renal function observed in this study may result in part from the sampling method used. Any sampling bias favouring inclusion of participants with poor renal function would have increased the risk of type 2 error in this study.
Recruitment of carers may have resulted in higher proportions of first-degree relatives and spousal recruitment. Spousal concordance of health risks and behaviours has been reported for many diseases, including CKD and other conditions influenced by renal risk factors, such as cardiovascular disease, hypertension, metabolic syndrome, and elevated fasting glucose levels [37, 38] .
We used a serum creatinine based equation to estimate renal function and eGFR [39] . Other studies have shown that cystatin-C may be a more accurate indicator of GFR than serum creatinine in populations with more extensive co-morbidities [40] . Cystatin-C accumulates in the blood of those with CKD and may reduce AD risk by binding Aβ and inhibiting its deposition in the brain [41] .
Major strengths of the present study were its reasonable sample size and extensive characterisation of the study population that enabled adjustment for major potential confounders. However, there are several potential limitations to our study. First, there may be residual confounding factors not measured in our sample that influence renal function but which have not been controlled for in our data. Second, any causal and temporal relationships between eGFR and AD cannot be determined due to the cross-sectional nature of our study, which prevents the inference of any causal or chronological relationship. Thirdly, the absence of direct measures of glomerular filtration rate limits the assumptions inferred from the eGFR formula which was based on a single laboratory measurement. Fourth, the potential for confounding bias may have been introduced through differences in the strategies for recruiting cases and controls. Fifth, the definition used for cognitively normal controls, MMSE ≥ 26, may have resulted in the inclusion of small number of individuals with prodromal AD. Finally, other methodological issues may further complicate the interpretation of our data. While the convenience sampling was instrumental in the recruitment of 570 participants in a timely manner, this approach may have inhibited subject demographics and limited the generalisability of conclusions. Future studies should aim to adopt a truly random approach to recruitment, using population records for identifying controls and a comprehensive AD patient database to sample cases.
This study provides cross-sectional evidence in a large sample that eGFR is not associated with AD in an elderly white population with poor renal function. Abbreviations: SD, standard deviation; OR, odds ratio; CI, confidence intervals; eGFR (CKD-EPI), Estimated glomerular filtration rate calculated using the CKD-EPI equation.
*Multiple logistic regression analysis adjusted for age (years), number of APOE e4 alleles, smoking (pack years), systolic blood pressure (mmHg), education (leaving school at or before 14), beta blockers.
